NASDAQ:AVROAvrobio Stock Price, Forecast & News

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 1.4% and is now trading at $17.77. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Avrobio.

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.11. View Avrobio's earnings history.

7 brokers have issued 12 month price objectives for Avrobio's shares. Their forecasts range from $13.00 to $43.00. On average, they anticipate Avrobio's stock price to reach $33.60 in the next twelve months. This suggests a possible upside of 89.1% from the stock's current price. View analysts' price targets for Avrobio.

News articles about AVRO stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avrobio earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Avrobio.

Avrobio saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,730,000 shares, an increase of 19.3% from the May 31st total of 1,450,000 shares. Based on an average daily volume of 344,800 shares, the short-interest ratio is currently 5.0 days. Approximately 5.9% of the company's stock are sold short. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Alector (ALEC), Bill.com (RVMD), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), I-Mab (BDTX), Beam Therapeutics (BEAM), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP) and Coherus Biosciences (CHRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Zynerba Pharmaceuticals (ZYNE).

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $17.77.

Avrobio has a market capitalization of $640.25 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

The official website for Avrobio is www.avrobio.com.

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]